Salipax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salipax

Quick Facts

Property Description
Active ingredient Fluoxetine Hydrochloride
Form Oral dosage forms (Capsules, Tablets, Oral Solution)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and central nervous system activity
Origin Synthetic (Bicyclic antidepressant derivative)

What Type of Medicine Is Salipax?

Salipax is a trade name for a prescription-only psychotropic agent that contains the active substance Fluoxetine, a synthetic compound categorized primarily as an antidepressant. The definitive chemical classification places it as a Selective Serotonin Reuptake Inhibitor (SSRI), a group of medications known for their targeted action in the brain. Fluoxetine is a second-generation antidepressant and a member of the SSRI class. This classification is recognized for its role in targeting monoamine neurotransmitters.

Composition, Form, and General Purpose

The composition of Salipax is based on the single active substance, Fluoxetine Hydrochloride, which is manufactured as a synthetic bicyclic compound. A key differentiating factor for the Salipax brand is its availability across multiple oral pharmaceutical preparations, including capsules, tablets, and a liquid oral solution, offering flexibility in patient use. The medication is prepared for oral administration, using standard pharmaceutical excipients as vehicles for systemic delivery.

The general purpose of Salipax is determined by its ability to induce serotonin reuptake blockade. This pharmacological effect temporarily prevents the reabsorption of the neurotransmitter serotonin back into the nerve cells, leading to enhanced concentration of serotonin available for communication in the brain. This mechanism contributes to the stabilization and elevation of mood, which is the primary general benefit of this pharmacological class. This sustained action defines its role in supporting the maintenance of mental equilibrium in individuals experiencing symptoms related to neurotransmitter imbalance.

Regulatory References

  1. MedlinePlus

What side effects are possible with Salipax?

Possible Side Effects and Safety Information

The safety profile of Salipax (Fluoxetine) is based on official classifications from government regulatory documents, defining both common and serious adverse reactions.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by their reported incidence in regulatory documentation, often grouped by frequency:

  • Very Common (affecting ge 1 in 10 patients) include Insomnia (difficulty sleeping), Diarrhea, Headache, and Nausea.
  • Common (affecting ge 1 in 100 to <1 in 10 patients) include Anxiety, Decreased libido, Somnolence (drowsiness), Tremor, and Dry mouth.

These effects are generally classified under System-Organ Classes, with the Nervous System and Gastrointestinal systems being frequently involved.


Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight specific, clinically significant reactions and restrictions that require adherence. These are explicitly noted in official prescribing information:

  • Serious Adverse Reactions include the documented potential for Serotonin Syndrome, Abnormal Bleeding, and Hyponatremia (low sodium levels). The risk of Suicidal thoughts and behaviors is officially noted, particularly in individuals under 25 years old.
  • Time-Related Patterns indicate that Serotonin Syndrome and the emergence of suicidal behaviors require close monitoring during treatment initiation and dose increases.
  • Population-Specific Considerations require that patients with substantial Hepatic Impairment use a lower or less frequent dose due to slower drug clearance. Additionally, the label requires screening for Bipolar Disorder before initiation due to the risk of activating a manic episode.

This structure ensures that the officially documented frequency of common effects is distinct from the critical safety constraints and mandatory warnings for serious adverse reactions.

Overdose and Emergency Response

Officially documented overdose of fluoxetine, the active substance in Salipax, primarily involves significant central nervous system (CNS) and cardiovascular events. Manifestations reported in human overdose experience include profound drowsiness, tremor, nausea, vomiting, and tachycardia. More severe manifestations officially associated with overdose are seizures and coma.

The regulatory profile highlights two critical life-threatening risks: the potential for Serotonin Syndrome—a severe complication characterized by hyperthermia, autonomic instability, and extreme agitation—and the risk of serious cardiac conduction abnormalities. These include QT prolongation and the potential for ventricular arrhythmia, such as Torsades de Pointes.

Urgent medical attention must be sought immediately if any severe symptoms are suspected. Official regulatory guidance mandates the immediate discontinuation of the drug and the initiation of symptomatic and supportive treatment upon the emergence of severe toxicity. As no specific antidote is known, continuous ECG monitoring is required due to the risk of cardiotoxicity. Furthermore, the long elimination half-lives of both fluoxetine and its active metabolite necessitate a prolonged period of clinical observation. This need for extended monitoring is particularly noted in patients with documented hepatic impairment, where drug clearance is delayed.

Therapeutic Uses of Salipax

What Salipax Treats: Main Uses and Benefits

Salipax is commonly used to help with the persistent, low, and pervasive mood, chronic lack of energy, and loss of interest that characterize Major Depressive Disorder (MDD). It is also used for a range of other conditions including Obsessive-Compulsive Disorder (OCD), specific eating disorders, Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD). This medication is applied in conditions marked by heightened patient distress and is relevant for both acute episodes and long-term supportive management of recurrent mood disturbances. This supportive use assists patients in managing motivation and concentration, contributing to improved day-to-day comfort.


The medication is considered relevant in clinical settings marked by the intense manifestations of OCD and Panic Disorder. It helps address symptom clusters that create noticeable functional strain, such as controlling involuntary, intrusive thoughts and the strong compulsion to perform repetitive rituals. The use is relevant for easing the intensity and frequency of severe anxiety, which supports the patient during difficult episodes and assists with maintaining functional stability.

“It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”

Salipax is also applied in specific conditions beyond general depression and anxiety. It supports the management of dysfunctional eating patterns, and may assist with managing the severity and frequency of binge eating episodes in Bulimia Nervosa. Additionally, it may be part of symptomatic management for the severe monthly mood swings associated with PMDD.


Quick Fact: Symptom Management Focus
Symptomatic Focus Psychological & Affective Distress
Benefit Aim Assisting with Maintaining Functional Stability
Target Context Acute Episodes and Recurrent Manifestations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Salipax (Fluoxetine) eligibility is determined by specific rules outlined in official regulatory labeling, defining populations for whom use is prohibited, conditional, or established.

Contraindicated Populations (Absolute Non-Eligibility)

Use of Salipax is strictly prohibited (contraindicated) for individuals with a known hypersensitivity to fluoxetine or any of its components. It is also prohibited for patients concurrently taking a Monoamine Oxidase Inhibitor (MAOI), Pimozide, or Thioridazine, due to the regulatory-mandated risk of drug-drug interactions.

Age-Related Eligibility

  • Adults (18+): Approved for all labeled uses.
  • Pediatric Patients: Approved for Major Depressive Disorder in patients 8 years and older and for Obsessive-Compulsive Disorder in patients 7 years and older. Use is not established for children younger than 7 years.

Condition-Based Restrictions

  • Hepatic Impairment: A lower or less frequent dosage may be appropriate for patients with cirrhosis or other liver issues due to altered drug elimination.
  • Reproductive Status: Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Breastfeeding is not recommended.
  • Conditional Use: Regulatory documents advise caution and/or pre-treatment screening for patients with a history of seizures, risk factors for QT prolongation, or Bipolar Disorder.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Salipax (fluoxetine) has been officially documented to interact with various medicinal products and substances, primarily due to its role as a potent inhibitor of the hepatic enzyme CYP2D6 and its serotonergic activity.

Clinically Significant Interaction Categories

Interacting Entity/Category Regulatory Concern/Mechanism
Monoamine Oxidase Inhibitors (MAOIs) Serotonin Syndrome risk (Pharmacodynamic)
CYP2D6 Substrates Increased plasma levels of co-administered drug (Pharmacokinetic)
Serotonergic Agents Serotonin Syndrome risk (Pharmacodynamic)
Drugs Affecting Hemostasis Increased risk of bleeding
QTc-prolonging Drugs Increased risk of heart rhythm abnormality

Interaction-Related Requirements and Restrictions

Co-administration with MAOIs (including linezolid and intravenous methylene blue) is restricted, necessitating a mandatory 14-day washout period after stopping the MAOI and a 5-week washout period after stopping Salipax before initiating an MAOI. The co-administration of Salipax with drugs such as Pimozide and Thioridazine is also restricted due to the combined risk of QTc prolongation and elevated plasma concentrations of these drugs. When combined with other serotonergic agents or drugs that interfere with blood coagulation (e.g., NSAIDs, aspirin, warfarin), caution is required due to additive pharmacodynamic effects.

Mechanism of Action

The core mechanism of Salipax involves the selective inhibition and blockade of the serotonin transporter (SERT) protein in the central nervous system. This molecular intervention prevents the reabsorption of serotonin ( 5-HT) back into the presynaptic neuron, thereby acutely raising the concentration of 5-HT available for postsynaptic communication. This blockade is maintained by the active metabolite Norfluoxetine and initiates a specific sequence of downstream effects.

The mechanism requires a period of cellular adaptation, as the acute rise in 5-HT initially activates inhibitory presynaptic 5-HT1 A autoreceptors (autoinhibition). Over several weeks, these autoreceptors desensitize, leading to increased serotonergic signaling as the physiological restraint is removed. This adaptation promotes neuroplasticity by increasing Brain-Derived Neurotrophic Factor (BDNF) expression and results in the long-term downregulation of the Hypothalamic-Pituitary-Adrenal (HPA) axis activity.

Secondary interactions, including antagonism at the 5-HT2 C receptor and agonism at the sigma1-receptor, also modulate the overall cellular response. This multi-target engagement and subsequent change in central signaling pathways forms the basis for the observed system-level physiological modulation.

Dosage and Administration Information

Salipax (Fluoxetine) is administered exclusively through the oral route, available in immediate-release capsules, tablets, an oral solution, and a delayed-release capsule for specific schedules. The medication may be taken with or without food as the presence of meals does not affect its bioavailability.

Official Dosing and Frequency Patterns

The dosage regimen is determined by the specific indication being addressed. For most adult indications, including Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), the initial dose is typically 20 mg once daily. The typical maintenance range is between 20 mg and 60 mg per day, with maximum doses for certain indications reaching 80 mg daily. The treatment of Bulimia Nervosa uses a fixed dose of 60 mg once daily.

Frequency is generally once daily, typically in the morning. However, a once-weekly schedule is approved for a 90 mg delayed-release capsule intended for maintenance use in MDD, initiated seven days after the last daily dose. For Premenstrual Dysphoric Disorder (PMDD), the schedule may be continuous daily or intermittent, involving administration for 14 days prior to menstruation through the first day of menses.

Administration Requirements

Dose adjustments should be made cautiously and gradually, often only after several weeks of consistent use. A lower or less frequent dosage (e.g., 20 mg every second day) is utilized for patients with significant hepatic impairment. A similar reduction may be advised for certain degrees of renal failure. Pediatric patients (aged 8 and older for MDD, 7 and older for OCD) begin treatment at 10 mg daily. If a daily dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped to maintain the established pattern.

Recent Clinical Evidence

Recent Clinical Evidence


Overview of Research

Research has explored the relationship between Salipax (which contains fluoxetine, an SSRI) and outcomes in patients with chronic non-specific low back pain (CNSLBP). Findings indicate that treatment with one class of antidepressant, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), was observed in connection with changes in pain levels over a 12-week trial period in adults with chronic low back pain. However, some reviews suggest these observed effects on pain intensity were generally small or trivial, with low to moderate certainty in the evidence.

One study specifically investigated reported pain levels and mobility scores, reporting a change in pain scores starting within four weeks of the study and continuing through the follow-up period. Low-certainty evidence for SSRIs suggests they may have little to no effect on pain intensity and disability in this population.


Combination Treatment and Scope

Studies have examined the use of the drug in combination with other therapeutic approaches, such as guided physiotherapy. One study evaluated whether combining the drug with physiotherapy was associated with a difference in relief speed compared to the drug alone. The specific findings varied depending on the type and duration of the associated physiotherapy program.

Clinical research has evaluated the drug across models managing both acute symptom flare-ups and long-term condition management. Further research is necessary to fully characterize any long-term effects of this class of medication in the treatment of chronic low back pain.


Tolerability Profile

Studies addressed the drug’s profile for tolerability and adverse events. The most commonly reported adverse events included mild gastrointestinal issues and temporary headache. These symptoms were typically mild and resolved without intervention. No significant side effects were reported in one study, which noted its tolerability across the study population. However, one class of antidepressants, SNRIs, was also associated with an increased risk of adverse events in controlled studies.

Frequently Asked Questions (FAQ)

Common questions about Salipax (FAQ)

Q: How quickly does Salipax usually start working?

A: Official product information indicates that the full therapeutic effect may not be observed right away. Clinical improvement for conditions like Major Depressive Disorder often requires several weeks of consistent use, with the maximum benefit typically seen after four weeks or longer. This timing is typical for psychiatric medications.

Q: How does Salipax affect the body's sleep pattern?

A: According to official adverse event reports, Insomnia (difficulty sleeping) is cited as a Very Common effect, meaning it affects many patients. Other central nervous system effects, such as anxiety and somnolence (drowsiness), are also listed as common side effects that may influence sleep quality.

Q: Are there any common foods or drinks that should be avoided while using Salipax?

A: The official labeling advises patients to avoid the consumption of alcohol during the course of treatment. This medication can be taken with or without food, as meals do not typically affect the drug's absorption.

Q: What considerations are there for using Salipax with kidney issues?

A: Official regulatory documents advise caution for patients with severe renal impairment (significant kidney issues). Official guidelines recommend considering a lower or less frequent dosage for this population.

Q: Can older adults use Salipax?

A: The medication is approved for use in the adult population, and the general label includes older adults. Studies indicate that patients aged 65 and older show a decreased risk of suicidal thoughts and behaviors compared to younger adults taking the medicine.

Q: Does Salipax interact with common over-the-counter pain relievers like ibuprofen?

A: Official interaction warnings note that the medication can increase the risk of abnormal bleeding when combined with drugs that interfere with blood coagulation. This category includes non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and aspirin.

Q: What are the signs of a serious side effect from Salipax?

A: Official drug information outlines several signs that require prompt medical attention. These serious symptoms include unsteadiness, confusion, agitation, hallucinations, fever, or the occurrence of abnormal bleeding and bruising. These signs may be related to conditions like Serotonin Syndrome.

Q: Can Salipax be used by women who are planning to become pregnant?

A: Official information advises reviewing this topic with a healthcare provider if planning a pregnancy. Use during pregnancy is permitted only if the physician determines that the potential benefit outweighs the potential risk.

Q: Are there special considerations for using Salipax with a history of heart problems?

A: Caution is advised for patients with a history of heart rhythm abnormalities, particularly those involving QTc prolongation. The drug has been documented to cause a lengthening of the QTc interval, which is an electrical measurement of the heart's rhythm.

Q: What is the purpose of the black box warning on Salipax?

A: Official product labeling includes a Boxed Warning, which is the most serious warning required by the FDA. This warning highlights the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to the age of 24, especially when treatment is first initiated or the dosage is changed.

Q: Can Salipax be used long-term?

A: Yes, the drug is approved by regulatory authorities for both the initial (acute) treatment and the long-term maintenance treatment of several chronic conditions. The duration of use is generally guided by established clinical protocols for maintenance treatment.

Q: What does 'contraindication' mean regarding Salipax use?

A: The term contraindication in official labeling refers to specific situations or conditions under which the drug should absolutely not be used. This prohibition is established because the risk of harm is judged to be too high, such as when combined with certain other medications.

Q: Is it necessary to take Salipax at the exact same time every day?

A: Official dosing schedules are generally for once-daily administration, often in the morning. While the label does not mandate an exact time, taking the medication consistently each day helps maintain stable concentrations of the medicine in the body.

Q: Can Salipax cause weight changes, and if so, is it weight gain or loss?

A: Official regulatory data indicates that changes in weight have been observed during clinical studies. Reports mention that significant weight loss has occurred in some patients, alongside other noted changes in appetite.

Q: Is it normal to feel a bit restless when first starting Salipax?

A: Regulatory documents indicate that symptoms of restlessness, anxiety, and agitation are potential adverse effects associated with the medicine. These feelings may be more noticeable when beginning treatment or when the dosage is adjusted.

Q: Does Salipax affect how long I can drive or operate machinery?

A: Regulatory documents caution that cognitive or motor performance may be impaired. Patients should be aware of how the medicine affects them before engaging in such activities as driving or operating hazardous machinery.

Q: What are the most common reasons why a doctor might prescribe Salipax?

A: The medicine is approved by regulatory bodies for the treatment of several specific conditions. These indications include acute and maintenance treatment of Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder.

Q: How long is a typical course of treatment with Salipax?

A: There is no fixed duration, as the medicine is approved for the maintenance treatment of chronic conditions like Major Depressive Disorder and Obsessive Compulsive Disorder. Therefore, the duration of use is often guided by the long-term clinical requirements of the treated condition.

Q: What happens if I stop taking Salipax suddenly?

A: Abruptly stopping the medication may lead to discontinuation symptoms, as noted in the regulatory documents. These symptoms can include dizziness, anxiety, agitation, mood changes, headache, and confusion. A gradual reduction is officially recommended to minimize these effects.

Q: Is it possible to have an allergic reaction to Salipax?

A: Yes, official safety information indicates that allergic reactions and skin rashes, including serious events, have been reported. A known hypersensitivity (severe allergy) to the active ingredient is an absolute contraindication, meaning the drug should not be used.

Q: Is there a generic version of Salipax available?

A: Yes, the active ingredient in Salipax, Fluoxetine Hydrochloride, is widely available as a generic medication. The generic version typically costs less than the original brand-name product.

Q: Why do official documents mention not combining Salipax with certain herbal supplements?

A: Regulatory warnings specifically advise caution or avoidance regarding the herbal supplement St. John’s Wort. Combining this supplement with the medication may increase serotonergic effects in the body, raising the potential risk of Serotonin Syndrome.

Q: Can Salipax make existing anxiety feel worse at first?

A: Yes, official safety data indicates that anxiety and agitation are potential side effects of the medication. These effects, along with restlessness, may be particularly noticeable during the initial weeks of treatment as the body adjusts to the medicine.

Q: Do I need to get blood tests while taking Salipax?

A: Routine blood testing is not commonly required for general use of the medication. However, testing the serum concentration may be useful in certain patients for purposes such as evaluating potential drug interactions or ensuring optimal levels.

Q: What if I take too much Salipax accidentally?

A: Official instructions advise contacting the poison control helpline if there is concern about an overdose. Emergency medical services should be sought if the individual collapses, has a seizure, or experiences difficulty breathing.

Q: Why is Salipax sometimes described as a 'first-line' medicine?

A: According to major international clinical guidelines and documents, the SSRI class of medicines, which includes the active ingredient in Salipax, is often categorized as a first-line pharmacological treatment option for specific mental health disorders, such as Obsessive Compulsive Disorder (OCD).

Q: Is Salipax considered a controlled substance?

A: No, this medication is not designated as a controlled substance by the DEA or other government regulatory bodies responsible for drug classification.

Q: Is Salipax known to cause 'brain fog' or difficulty concentrating?

A: Official regulatory information notes potential issues with thinking, concentration, and memory as possible adverse effects. These effects may be described by patients as feeling like 'brain fog.'

Q: Why is the official guidance strict about avoiding alcohol with Salipax?

A: Official guidance is strict because the medication may intensify the effects of alcohol on the central nervous system. Combining the two could lead to enhanced impairment of mental and motor skills.

Q: What should I tell my dentist before a procedure if I am taking Salipax?

A: Regulatory warnings mention the need to inform the dentist about taking this medication before any procedure. This is because the drug is documented to potentially increase the risk of bleeding due to its effect on blood clotting mechanisms.

Q: How long do the common side effects of Salipax typically last?

A: Regulatory information generally describes the common side effects, such as nausea or headache, as being mild and temporary. These symptoms frequently lessen or fully resolve over time as the body adjusts to the medication.

Q: Does the body become dependent on Salipax with regular use?

A: Official regulatory agencies have not classified this drug as physically addictive or having abuse potential. However, the requirement for a gradual reduction when stopping treatment is necessary to avoid potential discontinuation symptoms.

Q: Is Salipax a new medicine, or has it been around for a while?

A: The active ingredient in this medication, Fluoxetine, is a long-established compound. It was first approved by the FDA in the late 1980s and has been used widely since that time.

Q: Does Salipax interact with any medications for cold and flu symptoms?

A: Yes, regulatory documents indicate potential interactions with certain components found in cold and flu medicines. These components, such as dextromethorphan, may increase the risk of side effects like Serotonin Syndrome or cause potential cardiovascular issues.

Q: What is the process for stopping Salipax treatment safely?

A: Official guidance recommends that treatment should not be stopped abruptly. Instead, the dosage should be gradually reduced under a physician's supervision. This procedure is followed to help limit the occurrence and severity of potential discontinuation symptoms.

Q: Are there any known issues with Salipax and glaucoma?

A: Yes, official safety information advises caution for individuals with a risk of acute narrow-angle glaucoma. This is because the medication may cause mydriasis (pupil dilation), which could potentially increase the pressure within the eye.

How should Salipax be stored and disposed of?

Salipax (fluoxetine hydrochloride) must be stored under specific regulatory conditions to maintain stability and effectiveness. The medicine is required to be stored at Controlled Room Temperature, which is generally defined as 20^circ to 25 C (68^circ to 77 F), and should not be stored above 25 C in some regions. It must be kept in its original container, which should be tightly closed, and protected from moisture and excessive heat.

Child-Safety Storage

All regulatory information mandates that the medicine be kept out of the reach and sight of children, often recommending the use of locked safety caps for security.

Disposal Instructions

For unused or expired Salipax, the preferred disposal method is through an official drug take-back program or authorized collection site. The U.S. FDA also advises that this medication may be immediately flushed down the toilet if a take-back program is unavailable, due to the recognized high risk of accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salipax found in:

A-Z Index: